Skip to main content
SpringerLink
Log in

Treatment of anemia in the patient with heart failure

  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Opinion statement

Anemia is common among patients with chronic heart failure (CHF) and is associated with increased morbidity and mortality. The data suggest that correction of anemia in patients with CHF is beneficial in terms of exercise capacity, New York Heart Association functional class, hospitalisation rates, and quality of life. It is not known whether the correction of anemia in this group of patients will improve survival. Small-scale studies in patients with CHF have reported correcting anemia with erythropoietin and oral or intravenous iron. However, the optimal regimen for correction of anemia in patients with CHF has yet to be defined. Significant questions that remain to be answered are the following: which subset of patients with CHF would receive the greatest benefit, when to initiate anemia correction, what dosage of erythropoietin or other agent is appropriate, what target hemoglobin level is to be achieved, and how mortality will be impacted. A cost-benefit analysis is also required. At this point, the treatment of anemia in patients with CHF is not the standard of care and should only be initiated in an investigational setting.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. World Health Organization: Iron Deficiency Anaemia Assessment, Prevention, and Control: A Guide for Programme Managers. Geneva, Switzerland; 2001. http:// www.who.int/nut/documents/ ida_assessment_prevention_control.pdf.

  2. Anand I, McMurray JJV, Whitmore J, et al.: Anemia and its relationship to clinical outcome in heart failure. Circulation 2004, 110:149–154.

    Article  PubMed  Google Scholar 

  3. Ezekowitz JA, McAlister FA, Armstrong PW: Anemia is common in heart failure and is associated with poor outcomes. Circulation 2003, 107:223–225.

    Article  PubMed  Google Scholar 

  4. Mozaffarian D, Nye R, Levy WC: Anemia predicts mortality in heart failure. J Am Coll Cardiol 2003, 41:1933–1939.

    Article  PubMed  Google Scholar 

  5. Al-Ahmad A, Rand WM, Manjunath G, et al.: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 2001, 38:955–962.

    Article  PubMed  CAS  Google Scholar 

  6. Horwich TB, Fonarow GC, Hamilton MA, et al.: Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002, 39:1780–1786.

    Article  PubMed  Google Scholar 

  7. Kosiborod M, Smith GL, Radford MJ, et al.: The prognostic importance of anemia in patients with heart failure. Am J Med 2003, 114:112–119.

    Article  PubMed  Google Scholar 

  8. Silverberg DS, Wexler D, Blum M, et al.: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000, 35:1737–1744. Open-label, uncontrolled study of 26 anemic patients with class III—IV heart failure who demonstrated improvement in functional status, ejection fraction, hospitalization rate, and diuretic use when treated with erythropoietin and intravenous iron.

    Article  PubMed  CAS  Google Scholar 

  9. Androne AS, Katz SD, Lund L, et al.: Hemodilution is common in patients with advanced heart failure. Circulation 2003, 107:226–229. Hemodilution was found to have a 46% prevalence in 37 anemic patients with class II-IV CHF and to be associated with increased mortality.

    Article  PubMed  Google Scholar 

  10. Levine B, Kaiman J, Mayer L, et al.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990, 323:236–241.

    Article  PubMed  CAS  Google Scholar 

  11. Herrera-Garza EH, Stetson SJ, Cubillos-Garzon A, et al.: Tumor necrosis factor. A mediator of disease progression in the failing human heart. Chest 1999, 115:1170–1174.

    Article  PubMed  CAS  Google Scholar 

  12. Iverson PO, Woldbaek PR, Tonnessen T, Christensen G: Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 2002, 282:166–172.

    Google Scholar 

  13. Means RT: Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cells 1995, 13:32–37.

    Article  PubMed  Google Scholar 

  14. Macdougall IC: The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 1999, 14:1836–1841.

    Article  PubMed  CAS  Google Scholar 

  15. Beckingham I, Woodrow G, Hinwood M, et al.: A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant 1995, 10:2316–2320.

    PubMed  CAS  Google Scholar 

  16. Witte KKA, Clark AL: Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol 2002, 85:23–31.

    Article  PubMed  Google Scholar 

  17. Pittman J, Cohen P: The pathogenesis of cardiac cachexia. N EnglJ Med 1964, 271:403–409.

    Article  CAS  Google Scholar 

  18. Ansari A: Syndromes of cardiac cachexia and the cachectic heart: current perspective. Prog Cardiovasc Dis 1987, 30:45–60.

    Article  PubMed  CAS  Google Scholar 

  19. Anker SD, Ponikowski P, Varney S, et al.: Wasting as an independent risk factor for mortality in chronic heart failure. Lancet 1997, 349:1050–1053.

    Article  PubMed  CAS  Google Scholar 

  20. Witte KKA, Desilva R, Chattopadhyay S, et al.: Are hematinic deficiencies the cause of anemia in chronic heart failure? Am Heart J 2004, 147:924–930.

    Article  PubMed  Google Scholar 

  21. Silverberg DS, Wexler D, Sheps D, et al.: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol 2001, 37:1775–1880. Randomized controlled study of 32 anemic patients with class III—IV heart failure who demonstrated improvement in functional status, ejection fraction, hospitalization rate, and diuretic use when treated with erythropoietin and intravenous iron.

    Article  PubMed  CAS  Google Scholar 

  22. Mancini DM, Katz SD, Lang CC, et al.: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 2003, 107:294–299. Submaximal and maximal exercise capacity improved in patients with class III—IV heart failure randomized to receive erythropoietin for 3 months.

    Article  PubMed  CAS  Google Scholar 

  23. Epogen, epoetin alfa [package insert]. Thousand Oaks, CA: Amgen; 2004.

  24. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure [no authors listed]. Nephrol Dial Transplant 2004, 19(suppl 2):1–47.

  25. Besarab A, Bolton WK, Browne JK, et al.: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998, 339:584–590.

    Article  PubMed  CAS  Google Scholar 

  26. Macdougall IC, Ritz E: The normal haematocrit trial in dialysis patients with cardiac disease: are we any less confused about the target haemoglobin? Nephrol Dial Transplant 1998, 13:3030–3033.

    Article  PubMed  CAS  Google Scholar 

  27. Red Book: Pharmacy’s Fundamental Reference. Montvale, NJ: Thomson PDR; 2004.

  28. Aranesp, darbepoetin alfa [package insert]. Thousand Oaks, CA: Amgen; 2003.

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Columbia University College of Physicians & Surgeons, 622 West 168th Street, PH1273, 10032, New York, NY, USA

    Rebecca P. Streeter MD & Donna Mancini MD

Authors
  1. Rebecca P. Streeter MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Donna Mancini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Streeter, R.P., Mancini, D. Treatment of anemia in the patient with heart failure. Curr Treat Options Cardio Med 7, 327–332 (2005). https://doi.org/10.1007/s11936-005-0043-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11936-005-0043-x

Keywords

Search

Navigation